Results 11 to 20 of about 193,078 (253)

BONE METASTATIC DISEASE AND SKELETAL RELATED EVENTS – national recommendations

Zdravniški Vestnik, 2014
The national recommendations for bone metastatis disease, diagnostics and treatment options were defined at the interdisciplinary consensus meeting of basic scientists and clinicans.
Radko Komadina, Marko Špiler, Klemen Grabljevec, Marko Snoj   +3 more
doaj   +1 more source

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases

Frontiers in Oncology, 2020
ObjectivesThe prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated with modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated.Materials and ...
Marta Laganà, Cristina Gurizzan, Elisa Roca, Diego Cortinovis, Diego Signorelli, Filippo Pagani, Anna Bettini, Lucia Bonomi, Silvia Rinaldi, Rossana Berardi, Marco Filetti, Raffaele Giusti, Sara Pilotto, Michele Milella, Salvatore Intagliata, Alice Baggi, Alessio Cortellini, Hector Soto Parra, Matteo Brighenti, Fausto Petrelli, Chiara Bennati, Paolo Bidoli, Marina Chiara Garassino, Alfredo Berruti   +23 more
doaj   +1 more source

RNF219/α‐Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications

Advanced Science, 2021
The incidence of bone metastases in hepatocellular carcinoma (HCC) has increased prominently over the past decade owing to the prolonged overall survival of HCC patients. However, the mechanisms underlying HCC bone‐metastasis remain largely unknown.
Shuxia Zhang, Yingru Xu, Chan Xie, Liangliang Ren, Geyan Wu, Meisongzhu Yang, Xingui Wu, Miaoling Tang, Yameng Hu, Ziwen Li, Ruyuan Yu, Xinyi Liao, Shuang Mo, Jueheng Wu, Mengfeng Li, Erwei Song, Yanfei Qi, Libing Song, Jun Li   +18 more
doaj   +1 more source

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study

Swiss Medical Weekly, 2021
BACKGROUND International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer (mCSPC) with bone ...
Sandro T. Stoffel, Roger von Moos, Beat Thürlimann, Richard Cathomas, Silke Gillessen, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Anita Feller, Corinne Schär, Daniel Dietrich, Matthias Schwenkglenks, Judith E. Lupatsch, Michael Mark   +13 more
doaj   +1 more source

Skeletal-Related Events (SRE) in Prostate Cancer: A Report of Two Cases

Folia Medica Indonesiana, 2021
A skeletal-related event (SRE) is an event occurring due to bone metastasis in prostate cancer. SREs are usually marked by pain, pathological fractures, spinal cord compression, hypercalcemia, or bone metastasis requiring radiotherapy or operation.
Anak Agung Ngurah Oka Diatmika, Sunaryo Hardjowijoto   +1 more
doaj   +1 more source

Bone metastases and skeletal-related events from neuroendocrine tumors [PDF]

Endocrine Connections, 2015
Neuroendocrine tumors (NETs) metastasize to bone; however, a multi-institution evaluation of the natural history and complications of bone metastases across multiple NET subtypes has not, to our knowledge, previously been conducted.
Van Loon, Katherine, Zhang, Li, Keiser, Jennifer, Carrasco, Cendy, Glass, Katherine, Ramirez, Maria-Teresa, Bobiak, Sarah, Nakakura, Eric K, Venook, Alan P, Shah, Manisha H, Bergsland, Emily K   +10 more
openaire   +2 more sources

Bone health and therapeutic agents in advanced prostate cancer

Frontiers in Bioscience-Landmark, 2022
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of ...
Maria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, David Buchser, Jorge Pastor, Xavier Maldonado, Juan Zafra, Alison C. Tree, Renée Bultijnck, Paul Sargos, Piet Ost, Felipe Couñago   +11 more
doaj   +1 more source

Optimal bone health management strategies in patients with prostate cancer

Indian Journal of Urology, 2013
Bone health is affected in patients with prostate cancer, both by the disease and its treatment. Metastases to bone leads to pain, fractures, and spinal cord compression; bone loss due to androgen deprivation therapy (ADT) leads to osteoporosis and its ...
Gagan Prakash, Gagan Gautam
doaj   +1 more source

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis

Cancer Medicine, 2016
The purpose of this study was to estimate the risk of developing skeletal‐related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients.
Arif Hussain, Abdalla Aly, C. Daniel Mullins, Yi Qian, Jorge Arellano, Eberechukwu Onukwugha   +5 more
doaj   +1 more source

Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Bone Reports
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or ...
Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos   +9 more
doaj   +1 more source